RIGEL PHARMACEUTICALS INC (RIGL) Form 10-Q — Aug 4, 2026
Rigel Pharmaceuticals reported Q2 2026 total revenues of $78.7 million, down from $101.7 million a year earlier, though the prior-year quarter included a one-time $40.0 million non-cash release of a Lilly cost-share liability. Net product sales rose roughly 14% to $67.0 million, and net income was $17.3 million, or $0.88 per diluted share. VEPPANU (vepdegestrant), Rigel's fourth FDA-approved product, was in-licensed from Arvinas and Pfizer for up to $85.0 million in license fees including a $70.0 million upfront payment, plus up to $60.0 million in regulatory and $260.0 million in commercial milestones.
Key figures
- Eps
- 0.88
- Revenue
- 78703000
- Net Income
- 17290000
- Total Debt
- 39236000
- Revenue Yoy
- -22.6%
- Total Assets
- 521066000
- Cash Position
- 60816000
- Deal Value Usd
- up to $405.0 million VEPPANU license (up to $85.0 million license fee including $70.0 million upfront paid in June 2026, up to $60.0 million regulatory milestones, up to $260.0 million commercial milestones)
- Interest Rate
- 7.6
- Shares Outstanding
- 18679864
- Gavreto H1 Sales
- $20.3 million (-2% YoY)
- Rezlidhia H1 Sales
- $17.0 million (+29% YoY)
- Tavalisse H1 Sales
- $84.7 million (+24% YoY)
- Product Sales Q2 yoy
- +14%
- Eps Diluted Six Months
- 1.32
- Operating Cash Flow H1
- 33378000
- Product Sales Q2 2026
- 67015000
- Revenue Six Months2026
- 137521000
- Revenue Six Months yoy
- -11.3%
- Net Income Six Months2026
- 25944000
- Revolver Outstanding June30
- $40.0 million (repaid $32.0 million in July 2026, leaving $8.0 million)
- Veppanu Intangible Capitalized
- $70.6 million (15-year straight-line amortization)
- Contingent Milestone Payments Potential
- $652.1 million across collaboration agreements
- Cash Equivalents And Short Term Investments
- $95.3 million (vs $155.0 million at Dec 31, 2025)
Price after filing
Close on the filing date to close N calendar days later (from $38.06). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.